SBIR-STTR Award

HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating
Award last edited on: 1/31/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$1,993,762
Award Phase
2
Solicitation Topic Code
855
Principal Investigator
Mingyu Qiao

Company Information

Halomine Inc

1411 Hanshaw Road
Ithaca, NY 14850
   (334) 332-6198
   info@halomine.com
   www.halomine.com
Location: Single
Congr. District: 19
County: Tompkins

Phase I

Contract Number: 1R43AI155114-01
Start Date: 8/5/2020    Completed: 12/31/2021
Phase I year
2020
Phase I Amount
$250,255
In the US, about 1.7 million Healthcare-Associated Infections (HAls) occur in hospitals each year, resulting in 99,000 deaths and an estimated $20 billion in healthcare costs. According to previous reports, as much as one third of HAI cases can be attributed to environmental surfaces, namely “high touch” surfaces (e.g. bed rails, machine buttons, equipment), in a hospital. Self-sanitizing coatings, i.e. antimicrobial surfaces, are an ideal theoretical solution for eliminating persistent pathogens; however there has been no commercially available antimicrobial material which can fulfill all requirements of high-efficacy against pathogens: easy to apply, broad material compatibility, no pathogen resistance development, and cost-effective. That makes HaloFilm™ a breakthrough product. HaloFilm is a spray-on product that when dried leaves a thin transparent film on a surface. The film is a polymer composed of one monomer to stick to the surface, and another monomer that stabilizes chlorine, i.e. N-halamine. HaloFilm turns the surface into a chlorine battery so using even a household brand sanitizer will leave a surface covered with chlorine which can last longer than two weeks. HaloFilm has superior efficacy against pathogens compared to the most popular antimicrobial agent, silver, because it relies on the efficacy of chlorine which has decades of use, and broad-spectrum efficacy against pathogen without generating pathogens with resistance. In addition, we recently developed a formulation that include anti-fouling monomers, zwitterion moieties and poly(ethylene glycol). These additions to the polymer backbone mean that HaloFilm can be effective even without being charged with chlorine. This project will evaluate HaloFilm with these two anti-fouling monomers against HaloFilm without them. The best formulation will then be tested for efficacy and safety. HaloFilm is Halamine Inc.’s first product and is protected by exclusively licensed patents from Auburn University and Cornell University.

Public Health Relevance Statement:
PROJECT NARRATIVE Development of a new class of antimicrobial coating polymer products that can cost-effectively create “self-sanitizing” properties on hand-touch surfaces within healthcare facilities. To achieve this goal, we propose to demonstrate proof-of-concept regarding the antimicrobial functionality, durability, and safety of our newly invented polymer for hand-touch application on different substrate materials that are commonly used in the healthcare settings.

Project Terms:
Adhesions; Affect; Antibiotics; Antidotes; antimicrobial; antimicrobial drug; Antimicrobial Effect; Antimicrobial Resistance; Bacteria; base; Beds; Biological; Cessation of life; Charge; Chemicals; Chemistry; Chlorine; Clinical Trials; Consumption; cost; cost effective; cytotoxicity; Data; Development; Dopa; Effectiveness; efficacy testing; Equipment; ethylene glycol; Evaluation; Film; Formulation; fungus; Goals; Hand; Health Care Costs; Health care facility; health care settings; Health Personnel; healthcare-associated infections; Hospitals; Household; Human; In Vitro; in vitro testing; Infection; innovation; Intellectual Property; invention; Legal patent; Link; Medical Device; meetings; Methods; microbial; migration; minimal risk; monomer; Mussels; Nosocomial Infections; novel; Paint; pathogen; Patient Discharge; Patients; Patients' Rooms; Phase; Polymers; Procedures; Property; Proteins; Protocols documentation; relative effectiveness; Reporting; Residual state; Resistance; Resistance development; Rubber; Safety; Sanitation; Silver; Skin; skin irritation; Source; Stainless Steel; Structure; Surface; System; Techniques; Testing; Thinness; Time; tool; Touch sensation; Toxic effect; Universities; Vertebral column; Virus; Visual

Phase II

Contract Number: 2R44AI155114-02
Start Date: 8/5/2020    Completed: 11/30/2024
Phase II year
2023
(last award dollars: 2024)
Phase II Amount
$1,743,507

In the US, about 1.7 million Healthcare-Associated Infections (HAls) occur in hospitals each year, resulting in 99,000 deaths and an estimated $20 billion in healthcare costs. According to previous reports, as much as one third of HAI cases can be attributed to environmental surfaces, namely "high touch" surfaces (e.g., bed rails, machine buttons, equipment), in hospitals. Self-sanitizing coatings, i.e., antimicrobial surfaces, are an ideal theoretical solution for eliminating persistent pathogens; however there has been no commercially available antimicrobial material which can achieve high biocidal efficacy against pathogens with other necessary attributes, such as easy to apply, broad material compatibility, no resistance development to pathogens, and cost-effective. HaloFilm™ is a breakthrough product. HaloFilm is a spray-on product that when dried leaves a thin transparent film on a surface. The film is a polymer composed of one repeating unit with a functional group that adheres to a surface, and another functional repeating unit that stabilizes the chlorine. HaloFilm turns the surface into a chlorine battery so when it is used with a chlorine-based disinfectants it will allow the surface to be covered with the same level of chlorine found in a pool. HaloFilm is the only product that can pass EPA testing protocols as the supplemental residual antimicrobial coatings and films against bacteria and an enveloped virus surrogate for SARS-CoV-2. In fact, the EPA tested 20 of commercial products and none of the spray-on products achieved the 3-log reduction against Phi6 that HaloFilm achieved. HaloFilm is Halomine Inc.'s first product and is protected by exclusively licensed patents from Auburn University and Cornell University and will be brought to market in 2023 in collaboration with Diversey, a $2.7 billion global hygiene and infection control company. In this Phase II we will continue development of our product category by deepening our understanding of its efficacy against pathogens that are problematic in healthcare environments, extend HaloFilm's use by developing a wipe based HaloFilm product, and investigate potential for an optimum companion product that can maximize biocidal efficacy of the product in service.

Project Terms: